MedTrace Logo

The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?

NCT00988663 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-03-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether memantine will enhance the therapeutic of effect on depression and prevent memory and other cognitive problems caused by ECT.

Conditions

Interventions

DRUG

memantine

patient will receive 5mg daily for 7day then 10 mgm daily

DRUG

Placebo

will give placebo that looks like memantine

Sponsors & Collaborators

  • Jerrry L Lewis

    lead OTHER

Principal Investigators

  • Jerry L Lewis, MD · University of Iowa Hospitals and Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00988663 on ClinicalTrials.gov